Due to the difficulty in managing insulin in T1D patients, there are many clinical trials and pilot studies that have investigated the effect of utilizing the three main SGLT2 inhibitors, CANA [91], DAPA [92,93] or EMPA [94], as adjunctive therapies alongside insulin. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.